MINI FUTURE LONG - ASTRAZENECA | Market Closed - Euronext Paris 12:30:01 2024-05-03 pm EDT | ||
| 4.635 EUR | -2.22% |
|
| 1 month | +53.32% | ||
| 3 months | +66.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 4.615 | -2.64% | 70 |
| 24-05-02 | 4.74 | +1.07% | 80 |
| 24-04-30 | 4.69 | 0.00% | 77 |
| 24-04-29 | 4.69 | +1.63% | 82 |
| 24-04-26 | 4.615 | -0.97% | 96 |
Real-time Euronext Paris
Last update May 03, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| EX0FB | |
| ISIN | NLBNPNL1RHD5 |
| Date issued | 2022-03-28 |
| Strike | 8,079 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.96 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.215 € |
|---|---|
| Lowest since issue | 1.66 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.2
USD
Average target price
164.5
USD
Spread / Average Target
+8.76%
- Stock Market
- Certificates
- EX0FB Certificat
